Shots:

• The P-III (ACTIV-1) immune modulators trial evaluating Orencia (10mg/kg, IV) vs PBO when given with SoC in adults with COVID-19. The study was sponsored by NIH
• The findings revealed that Orencia treatment resulted in a significant but not statistically significant improvement in the 1EPs of time to recovery as determined by the day of hospital discharge. In 2EPs, (11% vs 15%) reduction in risk of death & improved clinical status @28 days, improvement in mortality was similar in both moderately & severely ill patients with 34.2% better odds of clinical improvement. The safety profile was consistent with no new safety signals
• The results will be published in a peer-reviewed scientific journal. BMS plans to discuss the data with the US FDA for the next steps

Ref: BMS | Image: BMS